News & Updates

ALXN1830, a humanized IgG4 antibody that blocks the neonatal Fc receptor (FcRn), is safe for the treatment of pemphigus in adults, reports a recent pilot trial. Aside from a good tolerability profile, ALXN1830 also induces rapid improvements in disease severity.

BF-200 ALA, an investigational drug, elicits high actinic keratoses (AK) clearance rates on the trunk, neck, and extremities when used with red light photodynamic therapy (PDT), a recent study has found.

The monoclonal antibody lanadelumab demonstrated long-term efficacy for patients with hereditary angioedema (HAE) who had received prophylactic lanadelumab for ≥12 months, according to findings from the post hoc analysis of the phase III HELP OLE* study presented at ACAAI 2021.

In patients with recessive dystrophic epidermolysis bullosa (RDEB), larger wound size is predictive of worsening skin disease severity and quality of life (QOL), reports a recent study. Worsening skin disease severity is significantly associated with key clinical manifestations.